In Vitro Activities of Omadacycline and Comparators against Anaerobic Bacteria

Por Stapert, Laure, Wolfe, Cindy, Shinabarger, Dean, Marra, Andrea, Pillar, Chris
Publicado no Antimicrob Agents Chemother (2018)

In Vitro Activity of Tigecycline against Gram-Positive and Gram-Negative Pathogens as Evaluated by Broth Microdilution and Etest

Por Pillar, Chris M., Draghi, Deborah C., Dowzicky, Michael J., Sahm, Daniel F.
Publicado em 2008

In Vitro Activity and Microbiological Efficacy of Tedizolid (TR-700) against Gram-Positive Clinical Isolates from a Phase 2 Study of Oral Tedizolid Phosphate (TR-701) in Patients w...

Por Prokocimer, Philippe, Bien, Paul, DeAnda, Carisa, Pillar, Chris M., Bartizal, Ken
Publicado em 2012

In Vitro Susceptibility Testing of Eravacycline Is Unaffected by Medium Age and Nonstandard Assay Parameters

Por Grossman, Trudy H., Pillar, Chris M., Sahm, Daniel F., Sutcliffe, Joyce A.
Publicado no Antimicrob Agents Chemother (2015)

In Vitro Activity of Doripenem, a Carbapenem for the Treatment of Challenging Infections Caused by Gram-Negative Bacteria, against Recent Clinical Isolates from the United States

Por Pillar, Chris M., Torres, Mohana K., Brown, Nina P., Shah, Dineshchandra, Sahm, Daniel F.
Publicado em 2008

Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae

Por Haas, Wolfgang, Pillar, Chris M., Hesje, Christine K., Sanfilippo, Christine M., Morris, Timothy W.
Publicado em 2010

Five-Year Longitudinal Assessment (2008 to 2012) of E-101 Solution Activity against Clinical Target and Antimicrobial-Resistant Pathogens

Por Denys, Gerald A., Pillar, Chris M., Sahm, Daniel F., O'Hanley, Peter, Stephens, Jackson T.
Publicado em 2014

Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United States

Por Draghi, Deborah C., Benton, Bret M., Krause, Kevin M., Thornsberry, Clyde, Pillar, Chris, Sahm, Daniel F.
Publicado em 2008

Besifloxacin, a Novel Fluoroquinolone, Has Broad-Spectrum In Vitro Activity against Aerobic and Anaerobic Bacteria

Por Haas, Wolfgang, Pillar, Chris M., Zurenko, Gary E., Lee, Jacqueline C., Brunner, Lynne S., Morris, Timothy W.
Publicado em 2009

Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates

Por Arhin, Francis F., Draghi, Deborah C., Pillar, Chris M., Parr, Thomas R., Moeck, Gregory, Sahm, Daniel F.
Publicado em 2009

Structure and DNA-binding properties of the cytolysin regulator CylR2 from Enterococcus faecalis

Por Rumpel, Sigrun, Razeto, Adelia, Pillar, Chris M, Vijayan, Vinesh, Taylor, Austin, Giller, Karin, Gilmore, Michael S, Becker, Stefan, Zweckstetter, Markus
Publicado em 2004

Tricyclic GyrB/ParE (TriBE) Inhibitors: A New Class of Broad-Spectrum Dual-Targeting Antibacterial Agents

Por Tari, Leslie W., Li, Xiaoming, Trzoss, Michael, Bensen, Daniel C., Chen, Zhiyong, Lam, Thanh, Zhang, Junhu, Lee, Suk Joong, Hough, Grayson, Phillipson, Doug, Akers-Rodriguez, Suzanne, Cunningham, Mark L., Kwan, Bryan P., Nelson, Kirk J., Castellano, Amanda, Locke, Jeff B., Brown-Driver, Vickie, Murphy, Timothy M., Ong, Voon S., Pillar, Chris M., Shinabarger, Dean L., Nix, Jay, Lightstone, Felice C., Wong, Sergio E., Nguyen, Toan B., Shaw, Karen J., Finn, John
Publicado em 2013